Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Ivermectin for covid-19 – the highlights

Written by | 29 Jul 2023

Ivermectin is an effective antiviral agent with a long record of successful use in human and animal parasite infestations. Its value as part of the early treatment for… read more.

The SAIVE trial for prevention of COVID-19

Written by | 8 Feb 2023

Professor Colleen Aldous is a research professor at in the School of Clinical Medicine at the University of Kwazulu-Natal in South Africa. She recently described the SAIVE trial… read more.

How the totality of evidence for ivermectin informs clinical practice

Written by | 7 Feb 2023

Colleen Aldous, Professor for Medical Research, University of KwaZulu-Natal explains how the evidence supporting the use of ivermectin for covid-19 came together to tell a compelling story. In… read more.

Addressing the totality of evidence for ivermectin

Written by | 6 Feb 2023

When assessing repurposed drugs in a pandemic situation, the totality of evidence should be considered rather than RCTs alone; had this been done the pandemic could have been… read more.

TOGETHER trial shows positive effect for ivermectin

Written by | 5 Feb 2023

The TOGETHER trial was widely reported as showing that ivermectin was not effective in covid-19, but a straightforward analysis of the results reveals a 59 per cent reduction… read more.

Ivermectin – is it safe and effective?

Written by | 4 Feb 2023

The best time to administer ivermectin is at the beginning of a covid-19 infection so that virus is killed and disease progression averted, according to Colleen Aldous, Professor… read more.

What makes the SAIVE study so good?

Written by | 3 Feb 2023

Professor Colleen Aldous is a research professor at the School of Clinical Medicine at the University of Kwazulu-Natal in South Africa. She recently described the SAIVE trial of… read more.

Ivermectin associated with lower mortality than remdesivir

Written by | 8 Mar 2022

An analysis of the records more than 41,000 patients who had covid-19 and were treated with either ivermectin or remdesivir showed that ivermectin was associated with significantly lower… read more.

Indomethacin RCT for covid-19 – features and conclusions

Written by | 9 Sep 2021

The RCT provides objective evidence of the effect of indomethacin and confirms the absence of adverse gastrointestinal effects; a future study could investigate indomethacin in severe covid-19, according… read more.

Randomised controlled trial of indomethacin for covid-19

Written by | 8 Sep 2021

Rapid resolution of symptoms and improved oxygen saturation were key features of the response to indomethacin compared with paracetamol, according to Dr Rajan Ravichandran and Professor Krishna Kumar…. read more.

Indomethacin provides rapid relief from covid symptoms

Written by | 7 Sep 2021

The interim results of a randomised comparison between indomethacin and paracetamol in covid-19 showed stark differences in efficacy, confirming the positive results of early trials of indomethacin. IMI… read more.

Applying the results of the ivermectin meta-analysis

Written by | 12 Aug 2021

The results of the ivermectin meta-analysis could have important implications for health policy. Dr Edmund Fordham, one of the co-authors of the review, describes how the findings could… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.